Global Chronic Immune Thrombocytopenia Market Research Report 2019-2026
Summary - A new market study, titled “Global Chronic Immune Thrombocytopenia Market - 2019-2026 ” has been featured on WiseGuyReports.
Chronic Immune Thrombocytopenia Market
Overview
Chronic Immune Thrombocytopenia (chronic ITP) is
an autoimmune disorder in which patients produce antiplatelet autoantibodies
and specialized white blood cells that destroy their blood platelets and, in
some cases, damage their megakaryocytes, causing a decrease in platelet
production.
The global chronic immune thrombocytopenia
market is expected to grow at a CAGR of 5.9% during the forecast period
(2019-2026)
Market Dynamics: Drivers,
Restraints, Opportunities Challenges:
Growing demand for therapeutics for the
treatment of rare blood related disorders, and increasing number of products
approved by the Food and Drug Administration are some of the major factors
driving the growth of the chronic immune thrombocytopenia (ITP) market
globally. According to National Organization of Rare Disorders (NORD), the
incidence of ITP among adults in the USA is estimated to be 3.3 per 100,000
adults/year. The prevalence is 9.5 cases per 100,000. The incidence of ITP
increases with age and is more common over the age of 60. Among adults (age
30-60) diagnosed with chronic ITP, there are 2.6 cases among women for every
case involving a male.
Several pharmaceutical companies conducting
research in rare diseases arena have received approvals from the FDA recently
which is boosting the growth of the chronic immune thrombocytopenia market. For
instance, in June 2019, the FDA approved Avatrombopag (Doptelet, Dova
Pharmaceuticals) for the treatment of adults with chronic immune
thrombocytopenia. In April 2018, the FDA approved Tavaliss, an oral spleen
tyrosine kinase (SYK) inhibitor which acts by impeding platelet destruction. In
December 2018, FDA approved Nplate (Romiplostim) for the treatment of pediatric
patients with chronic immune thrombocytopenia (ITP). In August 2018, Lusutrombopag
received FDA approval to treat thrombocytopenia adults with chronic liver
disease.
In addition, increasing drugs in pipeline offers
growth opportunities in the chronic immune thrombocytopenia (ITP) market.
Argenx’s Efgartigimod is currently (August 2019) tested in Phase 2 clinical
trials in immune thrombocytopenia (ITP). Rigel Pharmaceuticals, Inc.
manufactures drugs for treatment of rare diseases, immune, hematologic
disorders, and cancer. Phase 1 study of R835 and Phase 3 study with fostamatinib
in autoimmune hemolytic anemia are major pipelines of the company.
However, despite the increasing use of
Thrombopoietin Receptor Agonist (TPO-RA), many patients remain refractory to
available treatments. Current research is focused on combining therapies to
address multiple mechanisms of disease simultaneously which may result into
which may result into improved response rates and less toxicity.
Key Segment
Global Chronic Immune Thrombocytopenia Market By
Drug Class:
• Immunoglobulin
• Thrombopoetin (TPO) Receptor Agonist
• Steroids
• Platlet Stimulating Agents
• Others
Among these, Steroids holds significant market
share in 2018 and estimated to grow at a CAGR of 5.74% during the forecast
period. There are two main types of steroids: corticosteroids and
anabolic-androgenic steroids (or anabolics for short). Corticosteroid drugs,
like prednisone, are the standard initial treatment for patients with immune
thrombocytopenia ITP. They prevent the destruction of platelets by macrophages
within the spleen and liver thereby increasing platelet levels. Corticosteroids
are usually prescribed as a short-term treatment (3–4 weeks) because long-term
use leads to significant side effects that outweigh the benefits of reducing
the risk of serious bleeding.
Chronic ITP is cured either when the platelet
count falls below 30,000, or when there is bleeding. A steroid (such as
prednisone) is the first treatment; if steroids do not keep the platelet count
above 50,000, then it is treated with intravenous gamma globulin. If these
treatments are not effective and the platelet count remains dangerously low or
there is bleeding, other options such as removal of the spleen (splenectomy),
treatment with rituximab (Rituxan), Romiplostim (Nplate) or Eltrombopag
(Promacta, Revolade) are preferred. If these initial treatments aren't
effective, tranfusions, fostamatinib (Tavalisse), danazol (Danocrine) or
immune-suppressing medications (such as azathioprine (Imuran), cyclophosphamide
(Cytoxan, Neosar), or vincristine (Oncovin and others)) may be recommended.
Combinations of these treatments may be effective when individual treatments
are not.
Geographical Landscape
North America holds the dominant market share
for Chronic Immune Thrombocytopenia in 2018, and it is expected to maintain the
growth over the forecast period, owing to the rising prevalence of immune
thrombocytopenia, availability of treatment options and existence of effective
reimbursement policies. According to the National Organization for Rare
Disorders (NORD), the prevalence of immune thrombocytopenia among adults in the
US is estimated to be 3.3 per 100,000 adults/year. In the United States, an
estimated 30,000 new cases of ITP are diagnosed each year. Approximately 70% of
adults with ITP are women, and 70 percent of these women are under the age of
40 when diagnosed.
The Europe Chronic ITP market is also growing at
a significant CAGR during the forecast period, due to increasing cases of
chronic ITP coupled with rising research activities for the treatment of
chronic ITP. The European Medicines Agency (EMEA) has recognized chronic immune
thrombocytopenia (ITP) as an orphan disease, with nearly 50,000 adult patients
with chronic ITP in the European Union.
Competitive Landscape
The Chronic ITP market is concentrated by few
major players holding significant share in the market. Some of the major
players in the chronic immune thrombocytopenia market are: Novartis AG, Dova
Pharmaceuticals, F.Hoffmann-La Roche Ltd., CSL Limited, Amgen Inc., Kyowa Hakko
Kirin Co., Ltd., Shionogi Inc., Rigel Pharmaceuticals, Inc., Jiangsu Hengrui
Pharmaceutical Co., Ltd., and Shire and Ligand Pharmaceuticals, Inc.
The players are engaged in development of more
effective chronic ITP drugs to remain competitive in the global market. The key
players are adopting various growth strategies such as product launches,
mergers & acquisitions, partnerships, and collaborations which are
contributing to the growth of the Chronic Immune Thrombocytopenia market
globally. For instance,
In June 2019, the FDA approved Avatrombopag
(Doptelet, Dova Pharmaceuticals) for the treatment of adults with chronic
immune thrombocytopenia.
In December 2018, FDA approved Nplate
(Romiplostim) for the treatment of pediatric patients with chronic immune
thrombocytopenia (ITP).
In August 2018, Lusutrombopag received FDA
approval to treat thrombocytopenia adults with chronic liver disease.
In April 2018, the FDA approved Tavaliss, an
oral spleen tyrosine kinase (SYK) inhibitor which acts by impeding platelet
destruction.
FOR MORE
DETAILS: https://www.wiseguyreports.com/reports/4532929-global-chronic-immune-thrombocytopenia-market-2019-2026
About Us:
Wise Guy
Reports is part of the Wise Guy Research Consultants Pvt. Ltd. and offers
premium progressive statistical surveying, market research reports, analysis
& forecast data for industries and governments around the globe.
Contact Us:
NORAH
TRENT
Ph:
+162-825-80070
(US)
Ph: +44 203
500 2763 (UK)
Comments
Post a Comment